3218 – CIRCULATING MICRORNAS IN CEREBROSPINAL FLUID AND PLASMA: SENSITIVE TOOL FOR DETECTION OF SECONDARY CNS INVOLVEMENT, MONITORING OF THERAPY AND PREDICTION OF CNS RELAPSE IN AGGRESSIVE B-NHL LYMPHOMAS

Lymphoma with secondary central nervous system (CNS) involvement have poor prognosis and high mortality. Its diagnosis is based on conventional methods low sensitivity and/or specificity. MicroRNAs are short post-transcriptional gene regulators that remarkably stable detectable extracellularly in body fluids. We analyzed circulating microRNAs the cerebrospinal fluid (CSF) plasma of 162 patients aggressive B-cell non-Hodgkin's lymphomas (B-NHL) compared their levels CNS-involving versus systemic lymphomas, at during treatment CNS relapse. identified a set five oncogenic (miR-19a, miR-20a, miR-21, miR-92a, miR-155) CSF detect, sensitivity, lymphoma DLBCL, MCL, Burkitt lymphoma. Their combination into an oncomiR index enables separation from or nonmalignant controls specificity, Receiver Operating Characteristics (DLBCL AUC = 0.96, MCL 0.93, BL 1.0). Longitudinal analysis showed reflect efficacy clinical outcomes, allowing monitoring prediction. Similar effects were detectable, to lesser extent, plasma. In contrast methods, oncomiRs enable detection early residual involvement, as well parenchymal involvement. addition, increased before relapse (CSF plasma) improve CNS-IPI prediction risk. summary, study indicates potential use microRNA evaluation for B-NHL predicting therapy its detection.